Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 3/20 | 0.40 |
| ▸ | CLK1 | P49759 | 4/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486233 | 0.84 | PKM (0.37) | CYP3A4CLK1DYRK1ADYRK2DYRK1B | |
| SCHEMBL4476072 | 0.82 | DYRK1A (0.37) | MAP3K11CYP3A4TDO2CLK1DYRK1A | |
| SCHEMBL4482796 | 0.76 | KDR (0.53) | SMN1; SMN2ALDH1A1KIT | |
| SCHEMBL4470895 | 0.76 | DYRK1A (0.48) | CYP3A4DYRK1ADYRK1BMAPK1SMN1; SMN2 | |
| SCHEMBL4490967 | 0.76 | NPC1 (0.54) | CYP3A4DYRK1AROCK2ROCK1MAPK1 | |
| SCHEMBL4472148 | 0.75 | IDO1 (0.46) | TDO2MAPK1SMN1; SMN2ALDH1A1KIT | |
| SCHEMBL4491792 | 0.73 | MEN1 (0.57) | ROCK2ROCK1GAAKIT | |
| SCHEMBL4473208 | 0.72 | EPHX2 (0.50) | SMN1; SMN2KIT | |
| SCHEMBL4465203 | 0.72 | KDR (0.47) | MKNK2CLK1DYRK1ADYRK2DYRK1B | |
| SCHEMBL4481618 | 0.72 | ROCK2 (0.51) | MKNK2CYP3A4TDO2DYRK1AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| EP-1851198-B1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| CN-101115716-A | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA SA (FR) | 2008-01-30 | — | — | CN | disclosed |
| EP-1851198-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084996-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | PRMT1, ADPRS, RRM2B | MAP3K11 3529/4885MKNK1 4542/4885MKNK2 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.